Summary. To examine determinants of basal metabolic rate we studied 66 Type 2 (non-insulin-dependent) diabetic and 24 healthy age-and weight-matched control subjects with indirect calorimetry and infusion of [3H-3-] glucose. Eight Type 2 diabetic patients were re-studied after a period of insulin therapy. Basal metabolic rate was higher in Type 2 diabetic patients than in control subjects (102.8 + 1.9 J. kg LBM-J-min-1 vs 90.7 + 2.8 J-kg LBM-1. min-l;p < 0.01) and decreased significantly with insulin therapy (p < 0.01). The basal rate of hepatic glucose production was higher in Type 2 diabetic patients than in control subjects (1044.0 + 29.9 vs 789.3 + 41.7 gmol/min;p < 0.001) and decreased after insulin therapy (p < 0.01). Hepatic glucose production correlated positively with basal metabolic rate both in Type 2 diabetic patients (r = 0.49; p < 0.001) and in control subjects (r = 0.50; p < 0.05). Lipid oxidation was increased in Type 2 diabetic patients compared with control subjects (1.68_+0.05 vs 1.37 + 0.08 gmol.kg LBM '. min-i; p < 0.01) and decreased significantly after insulin therapy (p < 0.05). The rate of lipid oxidation correlated positively with basal metabolic rate both in Type 2 diabetic patients (r = 0.36; p < 0.01) and in control subjects (r = 0.51;p < 0.01). These data demonstrate that basal metabolic rate, rates of hepatic glucose production and lipid oxidation are interrelated in Type 2 diabetic patients. A reduction of the hepatic glucose production, however, is associated with a reduction in lipid oxidation, which in turn, may result in a reduction in basal metabolic rate.
Patients with Type 2 (non-insulin-dependent) diabetes mellitus and fasting hyperglycaemia are usually characterized by an elevated basal metabolic rate (BMR) [1] . An improvement in glycaemic control achieved by oral hypoglycaemic agents or hypocaloric diet is frequently fol lowed by a reduction in BMR [1] [2] [3] . This can be partially attributed to a reduced loss of calories in the urine, i.e. a reduction in glucosuria. On the other hand, even patients with no glucosuria can present with an elevated BMR. Therefore, other factors must be responsible. Fasting hyperglycaemia ensues as a consequence of increased hepatic glucose production (HGP) [4] , which is primarily due to an increased rate of gluconeogenesis [5] . Gluconeogenesis is an energy expensive process [6] , which could easily contribute to the increase in energy expenditure observed in these patients. It has also been suggested that an increased rate of lipid oxidation could contribute to the in creased rate of hepatic glucose production [7] , since betaoxidation of non-esterified fatty acids (NEFA) provide the abundance of ATP required for gluconeogenesis [8] . This was supported by a positive correlation between the rate of lipid oxidation and the rate of hepatic glucose production in individuals with normal and elevated (diabetic) blood glucose concentrations [7] . Limited data are available on how lipid oxidation and hepatic glucose production are related to the BMR in patients with Type 2 diabetes [1, 9, 10] . Whether these factors influence BMR similarly in Type 2 diabetic and control subjects is also not known.
The present study was therefore designed to examine whether the same factors were associated with BMR in hyperglycaemic non-obese Type 2 diabetic patients and healthy control subjects. To examine whether these factors could be influenced by treatment, a subset of diabetic patients was re-studied after having achieved near-normoglycaemia with insulin therapy.
Subjects and methods

Subjects
Sixty-six patients (32 females and 34 males) with Type 2 diabetes of 8 years (0-26 years) participated in the study. They were all treated with either diet alone or oral hypoglycaemic agents or both. The carbon dioxide concentration by a conventional infrared detector and oxygen concentration by a fast differential paramagnetic oxygen sensor. The monitor has a precision of 2.6 % for oxygen consumption and 1.0 % for carbon dioxide production. Protein oxidation was calculated from the urinary urea nitrogen excretion. Lean body mass was determined with the tritiated water dilution technique [12] . Briefly, 40 gCi of tritiated water (Amersham) diluted in normal saline was given as an intravenous injection. Blood samples for determination of tritiated water specific activity in plasma were drawn before and 80,100 and 120 min after the injection. 
Analytical determinations
The plasma glucose concentration was measured by the glucose oxidase method using a Beckman glucose analyzer II (Beckman Instruments, Fullerton, Calif., USA). Glycoh aemoglobin concentration in blood (HbA]c) was measured by high pressure liquid chromatography. The reference level for the assay was 5-7 %. Serum insulin was measured by a double-antibody radioimmunoassay (Pharmacia, Uppsala, Sweden). Plasma NEFA were measured with the microfluorometric method by Miles et at. [ 13] . [3H-3]-glucose specific activity was measured in duplicate on supernatants of 1 mol perchloric acid extracts of plasma samples, after evaporation of radiolabelled water.
Calculations
Basal hepatic glucose production was calculated by dividing the [3H-
3-]glucose infusion rate by the steady-state plateau of [3H-3-]gtucose specific activity achieved du ring the last 30 rain of the tracer infusion period. Net glucose, lipid and protein oxidation rates were calculated from indirect calorimetric measurements [11] and urinary urea nitrogen excretion.
Total body water was calculated from steady-state kinetic data assuming that 1 ml of plasma contains 93 % water. Lean body mass antidiabetic medication was stopped one week before the studies. Twenty-four age-and weight-matched healthy individuals (10 fe male and 14 maIe) with no family history of diabetes served as con trol subjects. The clinical and metabolic characteristics of the subjects are shown in Tables 1 and 2 . Eight Type 2 diabetic patients were re-studied after improved glycaemic control with insulin therapy for a H-month duration. Their clinical and metabolic characteristics are shown in Table 3 .
The study protocol was approved by the ethical committee of the Fourth Department of Medicine, Helsinki University Hospital, Hel sinki, Finland.
Methods
All subjects were studied with redirect calorimetry to obtain measures of substrate oxidation and BMR and with [3H-3-]glucose infusion to quantitate hepatic glucose production. Lean body mass was measured with tritiated water technique.
Hepatic glucose production was measured by the isotope dilution technique using [3H-3-]glucose (specific activity 7.8 Ci/mmol; Amersham International, Amersham, Bucks, UK) administered as primed constant (0.25 ~tCi/min) infusion for 150 min. The bolus dose was adjusted according to the degree of fasting hyperglycaemia (25-50 gCi). Blood samples for determination of [3H-3-]glucose specific activity were obtained at 10-min intervals during the last 30 min.
Indirect calorimetry was employed during 30 min to estimate net rates of carbohydrate and lipid oxidation and energy expenditure [11] _ A computerized, open-circuit system was used to measure gas exchange through a transparent plastic canopy (Deltatrac, Datex, Helsinki, Finland). Flow was measured by the air-dilution method, 
Statistical analysis
Data are expressed as mean and range or mean + SEM. Statistical analyses have been performed using BMDP computer programs (3D, 6D, 2R) . Differences between the ~oups were tested by MannWhitney rank sum test and correlations by linear regression analysis. To examine which variables were independently associated with BMR, variables which significantly correlated with BMR in the univat• analysis, were included in a multivariate analysis with BMR as dependent variable.
Results
The basal rate of hepatic glucose production was enhanced by 32 % in Type 2 diabetic patients compared with healthy control subjects (p < 0.001) ( Table 4 ). The rate of lipid oxidation was increased by 21 To in the Type 2 diabetic patients compared with the healthy control subjects (p < 0.01) ( Table 4 ). In addition, the BMR expressed per kg lean body mass was enhanced by 13 % in Type 2 diabetic patients compared with the healthy control subjects (p < 0.01), although the absolute rate of BMR did not differ between the two groups (Table 4) . Insulin therapy resulted in an increase in weight and improvement in glycaemic control (Table 3 ). Basal hepatic glucose production and energy expenditure decreased significantly after treatment (p < 0.01 vs before insulin therapy) and the rate of lipid oxidation was normalized (p < 0.05 vs before the insulin therapy). In healthy subjects the BMR correlated positively with weight (p < 0.001), body mass index (p < 0.05), lean body mass (p < 0.001), triglycerides (p < 0.05), hepatic glucose production (p < 0.05), glucose oxidation (p < 0.05) and with lipid oxidation (p < 0.001) ( Table 5 ). In these subjects the absolute rate of BMR was inversely correlated with age (p < 0.01). Similarly, in the Type 2 diabetic subjects, the absolute BMR was positively correlated with weight (p < 0.001), body mass index (p < 0.01), lean body mass (p < 0.001), hepatic glucose production (p < 0.001) and lipid oxidation (p < 0.001) and inversely correlated with age (p < 0.01) and glucose oxidation (p < 0.01) ( Table 6) .
The multivariate analysis clearly demonstrated that in both control subjects (70 %) and in Type 2 diabetic patients (63 %) lipid oxidation accounted for the major part of BMR. Lean body mass explained 20% of BMR in healthy control subjects and 15% of BMR in Type 2 diabetic patients.
Discussion
The Type 2 diabetic patients had fasting hyperglycaemia and significantly higher rates of BMR expressed per kg lean body mass than age-and weight-matched healthy control subjects. After a 40 % reduction of fasting plasma glucose with insulin in a subset of patients, the rate of BMR approached values observed in the control subjects. The results are thus in agreement with previously published data in Type 2 diabetic patients [1, 2, 9, 10, 14], but our results also extend to the comparison of BMR in weightmatched lean Type 2 diabetic subjects.
Since fat tissue is metabolically relatively inactive, muscle reflected by lean body mass has been considered as a major determinant of BMR [10] . In support of this, lean body mass showed a strong correlation with BMR in Obesity is usually associated with an increase in lean body mass, and therefore it has been difficult to discern from previous studies what is due to obesity and what is due to diabetes per se. However, differences in lean body mass cannot solely explain the differences in BMR between diabetic and control subjects, as lean body mass did not significantly differ between the two groups. In the multivariate analysis lean body mass could explain only 15 % of the BMR in Type 2 diabetic patients and 20 % in healthy control subjects, whereas lipid oxidation accounted for the major part of BMR. This is, of course, partially explained by the equation for calculating BMR from gas exchange measurements. Furthermore, a reduction in fasting hyperglycaemia achieved by insulin was associated with a reduction in BMR despite a tendency to increased lean body mass. Reduction in glycaemia achieved by tolazamide [1] and diet [14] also resulted in a reduction in BMR.
In both diabetic and control subjects the rate of hepatic glucose production correlated with BMR and the fasting plasma glucose concentration (r = 0.59; p < 0.001). This suggests that the higher the fasting plasma glucose concentration the higher the rate of hepatic glucose production and the higher the rate of BMR. In diabetic subjects gluconeogenesis accounts for about 75 % of hepatic glucose production [5] . The production of glucose by gluconeogenesis is an energy expensive process, since the production of I mol of glucose from pyruvate wilI require 6 mol of ATR It is therefore likely that the necessary en-965 ergy was provided by the increased rate of lipid oxidation, as the rate of lipid oxidation correlated positively both with BMR and hepatic glucose production. This was further supported by the strong relationship between the rate of lipid oxidation and BMR as demonstrated in the multivariate analysis. There are several other mechanisms by which an increased rate of lipid oxidation could stimulate gluconeogenesis. First, an enhanced rate of lipid oxidation results in accumulation of acetyl-CoA, which is known to stimulate pyruvate carboxylase, the key enzyme of gluconeogenesis [15] . Second, accumulation of acetyl-CoA inhibits oxidation of pyruvate thereby providing more pyruvate for gluconeogenesis [16] .
The reduction in BMR after improved glycaemic control was also associated with a reduction in the rates of hepatic glucose production and lipid oxidation. Under conditions of metabolic deterioration the increase in lipid oxidation may be necessary to compensate for the reduction in glucose oxidation [17] . The brain is dependent upon glucose as its energy source and this glucose could be provided by the enhanced rate of hepatic glucose production. On the other hand, it is not known whether the reduction in BMR observed during insulin therapy is due to a reduction in lipid oxidation or inhibition of the increased rate of giuconeogenesis.
Taken together the data from this study with simultaneous measurements of hepatic glucose production, BMR and lipid oxidation in non-obese Type 2 diabetic and healthy subjects demonstrate that these processes are interrelated. A reduction in hepatic glucose production is associated with a reduction in lipid oxidation, which in turn, will result in a reduction in BMR. This may help to explain the ease by which diabetic patients gain weight after improved glycaemic control.
